Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

St. Michael's Hospital to build first automated high-throughput zebrafish screening facility in Canada

Zebrafish are the new fruit flies.

27 Jan 2011

Merck Canada invests in CQDM to support biopharmaceutical research

Merck Canada has renewed its partnership with the Quebec Consortium for Drug Discovery by investing a further $5 million over five years in the organization so it can continue its support of biopharmaceutical research in Quebec.

27 Jan 2011

p38-targeted compounds hold promise for Alzheimer's disease treatment

Linda J. Van Eldik, director of the University of Kentucky Sanders-Brown Center on Aging, has been awarded a $750,000 grant to further her research into a possible treatment for Alzheimer's disease. The grant is from the Edward N. And Della L. Thome Memorial Foundation, and was one of only eight Awards in Alzheimer's Disease Drug Discovery Research to be given in the U.S. in 2010.

25 Jan 2011

New investigative tool may explore intracellular processes with unprecedented clarity

Nongjian Tao and his colleagues at the Biodesign Institute at Arizona State University have pioneered a new technique capable of peering into single cells and even intracellular processes with unprecedented clarity.

25 Jan 2011

Cancer Research UK launches new Centre in Glasgow

Cancer Research UK today (Thursday) launches a new Centre which will accelerate the pace of research in Glasgow and see the city become a world leader in the development of new treatments tailored for individual cancer patients.

21 Jan 2011

Cognition Therapeutics closes $2.5 million Series A1 financing

Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.

20 Jan 2011

Takeda Cambridge, Evotec enter collaboration to identify novel modulators against GPCR

Evotec AG today announced that it has entered into a collaboration with Takeda Cambridge Limited, to identify small molecule modulators against GPCR and Protease targets involved in various CNS and Metabolic diseases.

20 Jan 2011

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.

20 Jan 2011

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Targacept, Inc. today announced positive top-line results from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia.

20 Jan 2011

Researchers create biyouyanagin compound library

Using chemical compounds found in a Japanese plant as a lead and the clever application of ultraviolet light, a Scripps Research Institute team has created a unique library of dozens of synthetic compounds to test for biomedical potential. Already, one of the compounds has shown great promise in inhibiting replication of HIV particles and fighting inflammation.

19 Jan 2011

Cancer cells brought back under normal control

Scientists at The University of Nottingham have brought cancer cells back under normal control — by reactivating their cancer suppressor genes. The discovery could form a powerful new technology platform for the treatment of cancer of the breast and other cancers.

19 Jan 2011

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

Sanford-Burnham Medical Research Institute has entered into a collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to discover compounds for Alzheimer's disease and major psychiatric disorders.

18 Jan 2011

Cancer Research UK and CRT select 4 research groups to unravel role of cancer stem cells

Cancer Research UK and its commercial arm Cancer Research Technology (CRT), have established a team of scientists with expertise in cancer stem cell research to identify new targets to detect, monitor and treat cancer.

14 Jan 2011

Collaborative Drug Discovery receives additional grant for TB drug research

Collaborative Drug Discovery, Inc. (CDD) today announced that the Bill & Melinda Gates Foundation has extended its previous grant to CDD to create a novel database to spark collaborative efforts to discover more effective drugs against tuberculosis (TB). The TB bacillus infects approximately one third of the world's population and the disease kills over 1.5 million people every year.

14 Jan 2011

Vanderbilt, Scripps Research form partnership to open new institute

The Scripps Research Institute and Vanderbilt University have formed a partnership to advance science at the interface of chemistry and medicine, the institutions announced today.

14 Jan 2011

IDRI receives Bill and Melinda Gates Foundation multi-million dollar grant to identify new leads in TB

The Infectious Disease Research Institute today announced it has received a multi-million dollar grant from the Bill and Melinda Gates Foundation for "Chemical genomics for the identification of targets and leads in tuberculosis."

14 Jan 2011

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

VistaGen Therapeutics, Inc. and NuPotential, Inc. today announced that the National Heart, Lung and Blood Institute of the U.S. National Institutes of Health (NIH) has awarded to the companies a grant of approximately $500,000 to accelerate development of novel and safer approaches to generate patient-specific induced pluripotent stem (iPS) cells for regenerative medicine, drug discovery and drug rescue.

13 Jan 2011

Offensive protein generated by HPV handicaps defensive protein made by the human body

An international team of researchers is reporting that it has uncovered new information about human papillomavirus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection.

12 Jan 2011

NIDA awards Scripps Research, University of Pennsylvania $8.2M grant to develop tobacco addiction treatment

The Scripps Research Institute and the University of Pennsylvania School of Medicine have been awarded approximately $8.2 million over five years to develop novel compounds that could eventually become drug candidates for the treatment of tobacco addiction. Of the funds awarded, $5.7 million will go to Scripps Research, and $2.5 million to the University of Pennsylvania.

12 Jan 2011

PPD announces joint venture with TBL to develop novel biotherapeutics

PPD, today announced it has established a joint venture with Taijitu Biologics Limited in the area of the discovery of novel biotherapeutics. The joint venture, named BioDuro Biologics, expands PPD's capability to deliver unique, highly differentiated drug discovery services for biopharmaceutical companies across the globe.

10 Jan 2011

Drug Discovery News and Research

Further Reading

St. Michael's Hospital to build first automated high-throughput zebrafish screening facility in Canada

Merck Canada invests in CQDM to support biopharmaceutical research

p38-targeted compounds hold promise for Alzheimer's disease treatment

New investigative tool may explore intracellular processes with unprecedented clarity

Cancer Research UK launches new Centre in Glasgow

Cognition Therapeutics closes $2.5 million Series A1 financing

Takeda Cambridge, Evotec enter collaboration to identify novel modulators against GPCR

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Researchers create biyouyanagin compound library

Cancer cells brought back under normal control

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

Cancer Research UK and CRT select 4 research groups to unravel role of cancer stem cells

Collaborative Drug Discovery receives additional grant for TB drug research

Vanderbilt, Scripps Research form partnership to open new institute

IDRI receives Bill and Melinda Gates Foundation multi-million dollar grant to identify new leads in TB

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

Offensive protein generated by HPV handicaps defensive protein made by the human body

NIDA awards Scripps Research, University of Pennsylvania $8.2M grant to develop tobacco addiction treatment

PPD announces joint venture with TBL to develop novel biotherapeutics

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News